{
  "id": 16739563,
  "title": "After $1.9B impairment hit, Novartis stands by $12B bet on Avidity",
  "url": "https://urgent.news/2026/10/27/after-1-9b-impairment-hit-novartis-stands-by-12b-bet-on-avidity",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-27T10:57:52.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/novartis-stands-by-12b-bet-on-avidity-after-1-9b-impairment-hit/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Novartis’ $12 billion acquisition of Avidity Biosciences “remains absolutely on track,” CEO Vas Narasimhan said, after the company disclosed a $1.9 billion impairment charge on a failed late-stage neuromuscular disease asset it ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}